Patent SG-11201903867Y-A (SG)
Title: Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
Inventor: KING DAVID J
IPC: C07K16/30
Filed: 2017-11-01
Abstract: O 00 1-1 O O (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 11 May 2018 (11.05.2018) WIPO I PCT omit VIII °nolo III m H ioo 0111 VIII 110111110 (10) International Publication Number WO 2018/085469 A2 (51) International Patent Classification: A61K 39/395 (2006.01) C07K 16/30 (2006.01) (21) International Application Number: PCT/US2017/059619 (22) International Filing Date: 01 November 2017 (01.11.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/416,131 01 November 2016 (01.11.2016) US 62/427,775 29 November 2016 (29.11.2016) US (71) Applicants: ANAPTYSBIO, INC. [US/US]; 10421 Pacif- ic Center Court, Suite 200, San Diego, California 92121 (US). TESARO, INC. [US/US]; 1000 Winter Street North, Suite 3300, Waltham, Massachusetts 02451 (US). (72) Inventors: KING, David J.; 310 Cole Ranch Road, Encini- tas, California 92024 (US). KEHRY, Marilyn; 10440 Rock Creek Drive, San Diego, California 92131 (US). GHOSH, Srimoyee; c/o Tesaro, Inc., 1000 Winter Street North, Suite 3300, Waltham, Massachusetts 02451 (US). HUANG, Baochuan; c/o Tesaro, Inc., 1000 Winter Street North, Suite 3300, Waltham, Massachusetts 02451 (US). (74) Agent: ESPINO, Christine, G. et al.; Proskauer Rose LLP, One International Place, Boston, Massachusetts 02110 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: without international search report and to be republished upon receipt of that report (Rule 48.2(g)) (54) Title: ANTIBODIES DIRECTED AGAINST T CELL IMMUNOGLOBULIN AND MUCIN PROTEIN 3 (TIM-3) (57) : The disclosure provides antibody agents that bind to a T Cell Immunoglobulin and Mucin Protein-3 (TIM-3) protein. Particular immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide sequences are explicitly provided. Also provided are related nucleic acids, vectors, compositions, and methods of using the anti-TIM-3 antibody agent to treat a disorder or disease that is responsive to TIM-3 inhibition, such as cancer, an infectious disease, or an autoimmune disease.